Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer

A Phase II Trial of Adjuvant Treatment With Gemcitabine and Oxaliplatin Followed by Concomitant Gemcitabine and Radiation Therapy in Patients With Resected Pancreatic Adenocarcinoma

A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer.

Inclusion Criteria:

• Pathologically confirmed adenocarcinoma of the pancreas
• Patient have undergone a potentially curative resection
• No previous irradiation to the planned field
• Negative pregnancy test for child bearing women

Exclusion Criteria:

• Non-adenocarcinoma pancreatic cancer
• Treatment with any drug within the last 30 days that has not received regulatory approval.
• Serious systemic disorder
• Metastatic disease
• Pregnancy, breast feeding